Journal of Drugs in Dermatology - Tazarotene cream in combination with betamethasone valerate foam for plaque-type psoriasis
March 1, 2005 -- Abstract A combination of multiple agents is often required to achieve treatment success for plaque-type psoriasis. We report a case series of 10...
Journal of Drugs in Dermatology - A randomized controlled clinical trial assessing the effect of betamethasone valerate 0.12% foam on the short-term treatment of stasis dermatitis
May 1, 2005 -- Abstract Background: There are no published studies examining either the effectiveness of topical steroids in the treatment of stasis dermatitis or...
Skin & Allergy News - Biologics aren't all that's new in psoriasis Tx: a foam vehicle for betamethasone valerate and clobetasol propionate may enhance bioavailability
June 1, 2004 -- AMELIA ISLAND, FLA. -- Several promising new drugs for psoriasis patients are in development or en route to the United States, adding to the existing...
Business Wire - FDA Confirms Connetics NDA for Betamethasone Valerate Mousse Accepted as "Fileable"
February 25, 1998 -- PALO ALTO, Calif.--(BW HealthWire)--Feb. 25, 1998--Connetics Corp. (NASDAQ:CNCT) today announced that a New Drug Application (NDA) for betamethasone...
Business Wire - Stiefel Laboratories Will Enter Into Private Equity Minority Investment Agreement with The Blackstone Group
August 9, 2007 -- Partnering with The Blackstone Group Provides Robust Platform for Continued Growth CORAL GABLES, Fla. -- Stiefel Laboratories, Inc. announced today...
Business Wire - Stiefel Laboratories Receives FDA Approval of Olux-E Foam, 0.05% for Treatment of Psoriasis and Eczema
January 23, 2007 -- -- Company's Second Product in Emollient-Based Foam Delivery Vehicle -- CORAL GABLES, Fla. -- Stiefel Laboratories, Inc., the world's largest...
Business Wire - Connetics Announces Results of Special Stockholders Meeting
December 20, 2006 -- PALO ALTO, Calif. -- Connetics Corporation (Nasdaq:CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products,...
Business Wire - Connetics Announces Expiration of Hart-Scott-Rodino Waiting Period
December 15, 2006 -- PALO ALTO, Calif. -- Connetics Corporation (Nasdaq:CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products,...
Business Wire - Connetics Announces Special Meeting of Stockholders to Approve Merger With Stiefel Laboratories, Inc
November 17, 2006 -- PALO ALTO, Calif. -- Connetics Corporation (Nasdaq:CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products,...
Business Wire - Connetics Launches Verdeso Foam for the Treatment of Mild-to-Moderate Atopic Dermatitis in Children and Adults
November 8, 2006 -- Company Now Offers Complete Lineup of Topical Steroids to Meet Full Range of Potency Requirements PALO ALTO, Calif. -- Connetics Corporation...
